Is CBD Oil Legal in the U.S. and Canada?
June 26th, 2017
The cannabis plant is quite amazing. More than just a naturally growing herb that people choose to smoke for recreational and medical purposes, marijuana has recently risen to the surface as a potential cancer cure. Claimed to reduce pain, improve digestion and aid sleep (among many other things), ganja is said to have therapeutic benefits, of which patients are experiencing since the cannabis laws have been lifted in numerous states. However, there seems to be some confusion surrounding the topic of cannabidiol (CBD). Let’s expand on the subject.
What is CBD oil and what is it used for?
Cannabis oil is also referred to as cannabidiol (CBD). Extracted from hemp, cannabidiol (CBD) oil is one of 113 cannabinoids found in the plant. It is non-psychoactive and is contained in various medical marijuana products. These chemical compounds are secreted by the marijuana plant’s flowers. What makes CBD oil so unique is the fact that despite containing CBD and Tetrahydrocannabinol (THC), the highly active ingredient does not have the same effect. Unlike THC, CBD oil will not get you high. What it will do, however, is work well as an anti-inflammatory.
Some other uses of CBD oil include:
- Cigarette Addiction Cure
- Acne Treatment
- Diabetes Prevention
- Fibromyalgia Treatment
- Anti-Anxiety Effects
- Seizure Prevention
- Insomnia Cure
Aside from being consumed in oils, CBD can also be consumed in extracts and crystals. The hemp-derived oil is legal in all 50 states, not to mention 45 countries. A safe alternative to conventional treatments, CBD oil does not contribute to changes in body temperature, blood pressure, or heart rate. Furthermore, there is no need for a patient to acquire a prescription to enhance their health with CBD products, which has a calming effect on the nervous system and brain.
Legal Status of CBD Oil in the United States
In the States, it is legal for individuals and companies to sell CBD oil, so long as it has been imported from outside of the country. Many companies around the U.S. are using the term “hemp-derived CBD oil” when selling their products since this extract is claimed to be legal in all 50 states. In spite of that, other sources say how CBD oil is only legal in 16 states, so far. All cannabis extracts are considered Schedule I substances. This clarifying rule has since been challenged in a court of law. Possession seems to be riskier than selling, with CBD products remaining on the shelves around the country.
The states in which CBD-rich marijuana oil is legal as of April 2017 are as follows:
- North Carolina
- South Carolina
Florida, Idaho,and New York are also said to be in the process of broadening their medical marijuana horizons. Still, the U.S. Drug Enforcement Administration (DEA) is somewhat dubious about certain companies claiming that the ingredients in their products are derived from the marijuana plant’s sterilized seeds and mature stalks, rather than the actual plant. However, if CBD is not included in the Controlled Substances Act (CSA) Drug Schedule, surely it should be legal, right? Technically, yes. On the other hand, anything derived from the plant, be it the seeds, stalks, leaves or flowers, is deemed to be “marihuana”. “Natural cannabinoids in hemp products are exempt from DEA enforcement” is what CBD oil advocates are saying. The truth is this legality is only relevant for natural THC.
Legal Status of CBD Oil in Canada
In Canada, CBD can be prescribed as medication and according to new laws, producers of the Schedule II drug can legally sell CBD oils to people who have not been prescribed cannabis-based oils by their doctor. It was just last year that the Marihuana for Medical Purposes Regulations (MMPR) underwent these changes, following a Supreme Court ruling that spotlighted how patients should be able to treat their ailments with more than just dried marijuana. Canadian companies are still working hard to obtain licenses for the legal production of cannabis oils, with Peace Naturals Project Inc. in Ontario being the very first company to be granted the license.
As of August 2016, MMPR was replaced by the Access to Cannabis for Medical Purposes Regulations (ACMPR). The ACMPR is addressing medical marijuana issues by making the process of acquiring marijuana for medical purposes less challenging. Marijuana restrictions have since been lifted in a Governmental effort to legalize, regulate, and manage access to cannabis and CBD products. What this means is that medically needy individuals who have been authorized to use cannabis for medical purposes by their health care practitioner can do so by registering with Health Canada, registering with licensed producers, or designating someone to produce the CBD oil for them personally.
FDA Warnings for False CBD Oil Claims
Although CBD oil is widely legal, the U.S. Food and Drug Administration (FDA) are cracking down on placebo products. Back in February of last year, the federal agency distributed warning letters to numerous companies who were actively selling and profiting from products that contained CBD. The reason for the FDA’s action was all down to false claims, with some of the products claiming to cure serious diseases. Not only did this raise concern that customers would refrain from visiting a doctor and taking prescribed medication in favor of the CBD products but also, the FDA discovered that some of the products were completely free from CBD, despite what the scrutinized companies were protesting in their promotional and marketing efforts.
Thorough testing of CBD products is helping the FDA to separate the real companies that are producing effective CBD medicines from the untrustworthy companies that are promoting/selling bogus products. Scientifically valid investigations conducted by the FDA revealed how unsuspecting customers were acquiring cannabinoid-free oil and supplements from companies who were not recognized in the medical marijuana industry. They included Michigan Herbal Remedies, LLC, Dose of Nature, Healthy Hemp Oil, and Cali Stores. The warning letters demanded that the companies being investigated must “take prompt action to correct the violations”.
To learn more about new cannabis medical devices and other news, sign-up for our free newsletter using the form to the right.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.